<DOC>
	<DOCNO>NCT01017809</DOCNO>
	<brief_summary>The investigator propose totally abolish emesis ( vomit ) associate regimen oxaliplatin + topotecan add daily administration aprepitant ( Emend ) 17 day HT3 blocker routinely give day 1 15 .</brief_summary>
	<brief_title>Prolonged Emend Study ( NYU 03-67 ) Oxaliplatin Topotecan Previously Treated Ovarian Cancer</brief_title>
	<detailed_description>Patients enrol NCT0031361 , NYU 03-67 ( A Phase II study Oxaliplatin combine continuous infusion topotecan chemotherapy patient previously treat ovarian cancer NCI # 6317 ) receive oxaliplatin 85mg/m2 2-hr IV infusion D1 , 15 topotecan 0.4mg/m2/day continuous infusion 14 day begin D1 ( D1-15 ) 4 week cycle . On day 1 15 first cycle , patient also receive IV ondansetron 32 mg 10mg dexamethasone . Emend 125 mg give day 1 ; day 2-17 , patient give daily oral 80mg Emend without dexamethasone . On cycle 2-6 patient opt continue receive Emend : Emend 125 mg give day 1 ; day 2-17 , patient give daily oral 80mg Emend without dexamethasone . Following cycle 1 , Emend give conventional schedule ( i.e. , 1-3 , 15-17 ) unless discussion Principal Investigator , patient 's request receive drug cycle 1 deem desirable safe enter optional extension arm .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<mesh_term>Aprepitant</mesh_term>
	<mesh_term>Fosaprepitant</mesh_term>
	<criteria>All patient fulfil requirement enter study NYU 0367 eligible enter supplementary protocol Emend . Please see NCT0031361 eligibility . Patients enrol NYU 0367 ( NCT0031361 ) .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>ovarian</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>nausea</keyword>
</DOC>